The Danish biotech industry should give up the thought of taking a drug all the way from initial idea to final marketing and instead focus on individual phases of the development.
The appeal comes from Stig Jørgensen, CEO in the Life Science-group Medicon Valley Alliance, he wants people to consider funding and development in a new light.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app